– CANADA, Vancouver – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced the appointments of Greg Ciongoli and Bob Landry to its Board of Directors, effective August 10, 2025.
Greg Ciongoli and Bob Landry have also joined the audit committee.
About Greg Ciongoli
Greg Ciongoli is the Founder and Managing Partner of Adiumentum Capital Management, an investment firm that works closely with organizations on capital structure optimization and asset strategy.
Before founding Adiumentum, Greg Ciongoli spent over 16 years at The Baupost Group, where he served as Partner, Public Group Investing, and led investments in public and private companies across multiple industries and geographies. Over the course of his career, he has focused extensively on healthcare investments, corporate governance, and strategic transformation across both public and private markets.
His prior board member and observer experience includes Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Pharmaceuticals, Orexigen Therapeutics, Translate Bio, and others.
He serves on the board of directors of Atara Biotherapeutics.
Greg Ciongoli received his MBA from Harvard Business School and BA from Princeton University’s School of Public and International Affairs.
About Robert E. Landry
Bob Landry brings more than 30 years of global financial leadership experience across the pharmaceutical and biotechnology sectors. Most recently, he served as CFO and EVP, Finance at Regeneron Pharmaceuticals Inc.
Before Regeneron, Bob Landry spent over two decades at Wyeth and Pfizer, Inc., where he held various senior financial leadership roles, including SVP and Treasurer at Pfizer and CFO of Wyeth’s Research and Development division.
He serves on the board of directors of GanD, Inc. and Cytokinetics, Incorporated, where he serves as a member of the audit committee.
Bob Landry received his Bachelor of Business Administration from the University of Notre Dame.
“I believe Zymeworks’ novel approach to engineering fit-for-purpose biotherapeutics, through its proprietary technology platforms enabling antibody-drug conjugates and multispecific antibody therapeutics, combined with a strong financial foundation, positions Zymeworks well to execute with scientific and financial discipline,” said Robert E. Landry. “I am eager to contribute my experience to help guide Zymeworks through this meaningful time of growth and ensure focused resource allocation to support bringing critical medicines to patients.”
Troy Cox, who served on Zymeworks’ Board since 2019, has stepped down.
“We are deeply grateful to Troy for his six years of service as part of the Zymeworks Board, and sincerely thank him for his many contributions,” said Sue Mahony, Lead Independent Director of Zymeworks’ Board of Directors. “Troy has been an instrumental voice in shaping the Company’s strategy and supporting its growth, and we look forward to seeing his continued success.”
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting, and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.
For more: https://www.zymeworks.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.